APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

OUR FOCUS AREAS

NEWS

  • 4SC Signs Licensing and Development Agreement with Menarini for Resminostat in Asia-Pacific Excluding Japan

    Singapore - 16 April 2015 – 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, and Singapore based Menarini Asia-Pacific Holdings Pte. Ltd. ("Menarini AP") have announced that they have entered into a licensing and development partnership for 4SC's cancer compound resminostat for the Asia-Pacific region excluding Japan ("APAC").
  • Menarini Group 250 new employees in 10 months

    Florence, 02 December 2016: Menarini pharmaceuticals demonstrates a positive trend in the first 10 months of 2016, with 250 new employees in Italy and 230 around the world. The average age of the new employees is 29. The new hires are 60% male and 40% female and all of them are highly qualified with degrees or technical diplomas, and they join a total of over 16,000 staff in 130 countries around the world. In Italy, Menarini has manufacturing sites, research centres and offices in Florence, Pisa, Milan, L'Aquila, Pomezia, Bologna and Rapolano Terme (Siena).
  • Mitsubishi Tanabe Pharma Corporation Signs Licensing Agreement with A. Menarini Asia-Pacific for Spedra (Avanafil) in 10 Countries in Asia-Pacific

    Singapore, 26 February 2016 – Mitsubishi Tanabe Pharma Corporation (TSE: 4508), and Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd ("Menarini AP") have entered into a licensing agreement to commercialize and promote SPEDRA™ (avanafil). Menarini AP will receive exclusive licensing rights from Mitsubishi Tanabe Pharma Corporation to market Avanafil in China, Hong Kong, Macao, Taiwan, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam.

Dermatix

Live life to the fullest ‒ without worrying about scars.

Menarini Blog

Discover more about Menarini